Long-Term Safety Profile of Cosentyx
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other conditions, shows no unique age-related risks identified in long-term trials or post-marketing data up to 5 years. Safety remains consistent across adults 18+, with no dose adjustments needed for age alone.[1][2] Common risks like upper respiratory infections, diarrhea, and nasopharyngitis occur at similar rates in older and younger patients.
Risks in Patients Over 65
In trials including patients up to 85, those over 65 (about 10-15% of participants) had higher overall adverse event rates, mainly due to comorbidities rather than Cosentyx itself. Serious infections rose slightly (e.g., 4.5% vs. 2.8% in under-65s), but no causal link to age-specific vulnerability. Opportunistic infections like candidiasis or tuberculosis reactivation carry general warnings, with closer monitoring advised in elderly due to weakened immunity.[1][3]
Common Long-Term Risks Regardless of Age
- Infections: Increased risk of upper/lower respiratory, urinary tract, and fungal infections; rates stable over 5 years (14-20% yearly).[2]
- Inflammatory bowel disease: New-onset or flares in 1-2% of patients, monitored via symptoms.[1]
- Hypersensitivity: Rare anaphylaxis; long-term exposure doesn't amplify.[3]
No evidence of cumulative organ damage like liver/kidney toxicity in extended use.
How Age Influences General Risks
Elderly patients face amplified baseline risks from polypharmacy, reduced renal function (Cosentyx clearance drops 20-30% in severe impairment), or frailty, indirectly heightening infection or fall risks from fatigue. Trials report no increased malignancy or cardiovascular events tied to long-term use or age.[2][4] Vaccinations (e.g., pneumococcal) recommended pre-treatment for all, especially seniors.
Monitoring and Mitigation for Older Users
Regular checks for infections, TB screening before and during therapy, and IBD symptom tracking apply universally. No age-stratified guidelines beyond standard precautions; discontinue if serious infection occurs.[1][3] Real-world data from registries like SCULPTURE (5-year follow-up) confirm sustained tolerability.[2]
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: Bissonnette et al., J Am Acad Dermatol (2018) - 5-year safety data
[3]: FDA Label for Secukinumab
[4]: EMA Assessment Report